[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaping\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaping":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,54,80,108,131,160,186,226,253,279,295,325,348,377,406],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100053678","phase-4-varenicline-and-accelerated-transcranial-magnetic-stimulation-tms-for-quitting-nicotine-use-pilot-study-100053678",false,"NCT07145866","Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)","Evaluation of Varenicline and Accelerated TMS for Reduction of Nicotine Use","V-TMS","Inclusion Criteria:\n\n* Age ≥ 18 and ≤65;\n* The ability to give written, informed consent;\n* Fluency in English;\n* Reported interest in quitting nicotine vaping or smoking within the next month;\n* Nicotine dependence, as defined by a score of ≥4 on the 10-question E-cigarette Dependence Inventory (ECDI) or Fagerström Test for Nicotine Dependence (FTND);\n* Smoke or vape nicotine daily for at least the past 90 days, as confirmed by self-report and timeline follow-back methods;\n* Saliva cotinine \\>30ng\u002FmL;\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Use of smoking cessation pharmacotherapy in the past month;\n* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study;\n* Prior adverse drug reaction to varenicline;\n* Contraindication to D-Cycloserine (including allergy to D-Cycloserine, significant renal impairment or known kidney disease, pregnancy)\n* Receiving or planning to receive other TMS treatments or investigational drugs during course of participation\n* Contraindications to TMS (including seizures, metallic implants, severe existing tinnitus, etc.);\n* Contraindications to MRI (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia);\n* Inpatient psychiatric hospitalization or suicide attempts in the past six months, or recent active suicidal ideation or suicidal behavior identified at enrollment or baseline visits;\n* History of seizures and\u002For history of TBI subtypes associated with elevated seizure risk (e.g. penetrating injury and intraparenchymal hemorrhage)\n* History of unstable neurological illness or major medical illness, such as epilepsy or renal impairment, in the past six months, unless clearly resolved;\n* In the opinion of the investigators, evidence of active problem substance use severe enough to compromise ability to safely participate;\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., claustrophobia, unable to tolerate TMS or MRI procedures, etc.).","ALL","18 Years","65 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn if a combination of varenicline and enhanced accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS with a single dose of D-Clycloserine to varenicline + sham (inactive) aTMS with a placebo pill to see the effect of enhanced aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active enhanced aTMS + varenicline lead to higher abstinence rates and lower nicotine craving?\n\nParticipants will be asked to:\n\n* Complete 2 brain MRI scans\n* Take varenicline every day for 12 weeks\n* Quit using nicotine products at the end of the second week of varenicline\n* Complete one day of up to 20 TMS treatments\n* Take a single dose of D-Cycloserine medication on the day of TMS treatment\n* Complete 12 brief, weekly follow-up visits\n* Complete a brief daily survey each day that they take the study drug",[28,29,30,31,32],"Nicotine Dependence","Transcranial Magnetic Stimulation","Vaping","Smoking Cessation","Smoking (Tobacco) Addiction",[30,34,35,36,37,38,29,39,40],"Smoking","Nicotine","Adults","Cessation","Varenicline","TMS","D-Cycloserine","RECRUITING","2026-07-09",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":22},"2026-08",{"date":49,"type":22},"2027-12",{"name":51,"class":52},"Massachusetts General Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":18,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":53},"100574900","behavioral-intervention-for-youth-to-promote-vaping-cessation-100574900","NCT06765291","Behavioral Intervention for Youth to Promote Vaping Cessation","VIA","Inclusion Criteria:\n\n* Age 14-18 inclusive\n* Self-report of at least weekly nicotine vaping (or use of other non combusted nicotine products, \"vaping\") for the prior ≥3 months\n* Self-report of no regular combusted tobacco use (i.e., 5 or more days of smoke smoked tobacco use per week) prior to enrollment and exhaled CO \\\u003C10 ppm for those with an in person baseline visit\n* Report willingness to try to quit or reduce vaping in the next 30 days\n* Able to understand study procedures and read and write in English or Spanish\n* Have a parent or legal guardian who is able to participate in the opt out process\n* Competent and willing to provide written informed consent (if age 18) or assent (if under 18)\n\nExclusion Criteria:\n\n* Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion)\n* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study\n* Unwilling to provide saliva or urine samples\n* Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol","14 Years",{"count":63,"type":22},400,[65],"NA","This study will test the hypothesis that the QuitVaping (QV) intervention and additional texting support will improve nicotine abstinence rates in adolescents as compared to Enhanced Usual Care (EUC: education about nicotine, vaping and addiction, advice to quit vaping, referral to TIQ texting support). Approximately 400 adolescents will be randomly assigned to one of two arms (1) QuitVaping intervention plus texting support to quit vaping and (2) EUC only.",[30,68,28],"Vaping Teens",[30,70,71],"Nicotine Depedence","Vaping Cessation","2026-06-26",{"date":74,"type":45},"2026-06-29",{"date":76,"type":45},"2025-06-18",{"date":78,"type":22},"2029-02-21",{"name":51,"class":52},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":106,"locationsCount":53},"100634522","social-media-support-groups-for-adolescent-vaping-cessation-100634522","NCT07540780","Social Media Support Groups for Adolescent Vaping Cessation","Inclusion Criteria:\n\n1. English literacy\n2. Age between 13-21 years (group participants) or 18+ (coaches, peer mentors)\n3. Indicate they use social media \"most\" (\\>= 4) days per week (group participants)\n4. Have vaped at least once per week in the past 30 days (90 percent of participants) (group participants)\n5. Access to a computer or mobile phone with photo capability to verify abstinence from vaping (group participants)\n6. Indicate they are considering quitting or are interested in quitting with the next 6 months or within the next 30 days (group participants)\n7. Currently reside in California, Minnesota, Oklahoma, or South Carolina\n\nExclusion Criteria:\n\n1. No English literacy\n2. Age under 13 or over 21 (group participants) or under 18 (coaches, peer mentors)\n3. Insufficient social media use (3 or fewer days per week) (group participants)\n4. Have not vaped at least once per week in past 30 days (group participants)\n5. No access to computer or mobile phone with photo capability to verify abstinence from vaping (group participants)\n6. Not considering or interested in quitting vaping in the next 30 days or 6 months (group participants)\n7. Not a resident of California, Minnesota, Oklahoma, or South Carolina",true,"13 Years",{"count":89,"type":22},60,[65],"The purpose of this study is to pilot test feasibility and acceptability of the Quit the Hit Toolkit, a social media-based nicotine vaping cessation program for adolescents and young adults, adapted for use in community settings.",[30,71,28],[94,95,96,97,98,99],"single arm","pilot","intervention","vaping","adolescent","young adult","2026-06-04",{"date":102,"type":45},"2026-06-08",{"date":104,"type":45},"2026-04-15",{"date":47,"type":22},{"name":107,"class":52},"University of California, San Francisco",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":86,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":53},"100474159","early-detection-of-vaping-related-vascular-diseases-100474159","NCT05454267","Early Detection of Vaping-related Vascular Diseases","ENDS","Inclusion Criteria:\n\nVapers Group:\n\n1. Current electronic cigarette (EC) Puff Bar users defined as using EC either daily or occasionally in the past 30 days for at least 6 months, and with 5% nicotine concentration pods.\n2. Adults aged 18-40 years\n\nHealthy Group:\n\n1. Healthy never smokers, never vapers\n2. Adults aged 18-40 years\n\nExclusion Criteria:\n\n1. Current or past smoking of tobacco cigarette (TC) or other tobacco\u002Fnicotine products (e.g., smokeless tobacco, Hookah) or marijuana will be excluded from the study.\n2. Subjects with self-reported history of chronic health problems including asthma, chronic obstructive pulmonary disease (COPD), morbid obesity (BMI\\>40 kg\u002Fm2), hypertension or diabetes\n3. Pregnant or breastfeeding women","40 Years",{"count":117,"type":22},90,"OBSERVATIONAL","The purpose of this study is to determine how vaping affects blood vessels, in particular if early damage occurs in the lung vessels.",[30,121],"Blood Vessel Injury","2026-05-13",{"date":124,"type":45},"2026-05-15",{"date":126,"type":45},"2022-09-12",{"date":128,"type":22},"2027-12-31",{"name":130,"class":52},"University of Miami",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":53},"100636653","tubsis-20---tobacco-use-behavioral-support-and-intervention-system-100636653","NCT07568483","TUBSIS 2.0 - Tobacco Use Behavioral Support and Intervention System","Effectiveness of an Internet-based, Self-help, Asynchronized Behavioral Therapy With Mindfulness Approach for Adults With Tobacco Smoking or Vaping to Support Adults in Reducing Tobacco Smoking and Vaping in Switzerland and Türkiye","TUBSIS_2_0","Inclusion Criteria:\n\n* Age: 18 years or older\n* Smoking status:\n\nSmoked on ≥1 day in the past 30 days, and\u002For Smoked at least 100 cigarettes in lifetime\n\n* Internet access: Stable internet connection and access to a smartphone, tablet, or computer during interaction of the TUBSIS 2.0 web-based platform.\n* Language: Sufficient reading and listening comprehension in the study language (German, English or Turkish)\n* Contact: Valid email address and phone number (optional) for study communication, reminders and incentive payments\n* Consent: Provided electronic informed consent on TUBSIS 2.0 web-based platform which is developed and administrated by ISGF.\n* Study procedures: Agreement to randomization (intervention or control) and completion of study assessments at four time points (baseline, mid-intervention, post-intervention and 8-week follow-up)\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria are excluded.",{"count":140,"type":22},406,[65],"Background:\n\nTobacco smoking and vaping remains public health concern, with many adults continuing to experience difficulties accessing appropriate support for smoking cessation in Switzerland and Türkiye. Structural barriers, including stigma related to attempting to quit, limited financial and time resources, low awareness of the health risks associated with tobacco smoking- and vaping-reduce engagement with traditional services. TUBSIS 2.0 aims to address these access inequities by providing a fully remote, anonymous and free internet-based program tailored to diverse adult populations in both countries.\n\nObjectives:\n\nThe \"TUBSIS 2.0: An Adaptation Study of Tobacco Addiction Support Programme - TUBSIS for Tobacco Users in Switzerland and Türkiye\" project aims to support readiness to reduce or quit tobacco smoking\u002Fvaping, improve well-being and self-compassion and strengthen health-related behaviors. The intervention targets German-, English-, and Turkish-speaking adults and includes mindfulness-based strategies for quitting or reducing tobacco smoking and vaping. Motivation to cease tobacco smoking\u002Fvaping varies considerably across the lifespan. Younger individuals may perceive smoking\u002Fvaping cessation as unnecessary, often due to limited awareness of long-term health risks or a sense of invulnerability. In later adulthood, although addiction tends to be more deeply established, many individuals hesitate to attempt cessation because of concerns about the psychological and behavioral challenges associated with the process. It is therefore essential to provide individuals with support that helps them understand the cessation process, prepare for the challenges that can be expected and identify strategies that align with their psychological needs. Such strategies may include stress management and self-compassion practices that can be utilized before, during and after cessation attempts. TUBSIS 2.0 offers structured and accessible guidance to support this preparation by providing a clear, evidence-based pathway for individuals at different stages of readiness to change.\n\nMethods:\n\nTUBSIS 2.0 is a web-based, individual and asynchronous program consisting of eight modules delivered over four weeks. A total of 406 participants will be recruited and randomly assigned to either the intervention or control group. Data are collected anonymously at four measurement points (baseline, mid-term, post-term and 8-week follow-up) from participants. The program focuses on supporting participants' reducing or quitting tobacco smoking or vaping; to increase their readiness for smoking\u002Fvaping cessation, mental well-being, self-compassion and stress management with mindfulness strategies.\n\nWithin the Health Action Process Approach (HAPA), the process of behaviour change is conceptualised as a dynamic, non-linear process that progresses through motivational and volitional phases. TUBSIS 2.0 has been adapted to reflect this structure by integrating phase-specific components. These components include modules that enhance risk awareness and outcome expectancies, planning and self-regulation tools to support action initiation and mindfulness-based strategies that are embedded throughout all phases to strengthen self-efficacy and coping. By addressing these shifting needs across the change process, the programme provides a responsive and theory-driven pathway for reducing\u002Fquitting tobacco smoking or vaping.\n\nRelevance:\n\nTUBSIS 2.0 is highly relevant to public health priorities, as it provides a cost-effective, scalable and environmentally sustainable intervention that eliminates barriers commonly associated with traditional cessation services. By requiring no travel, printed materials or in-person appointments, the programme offers equitable access to adults across all age groups, genders and diverse migrant communities in Switzerland and Türkiye. Its multilingual and culturally adapted structure addresses significant service gaps for populations that are underserved or hesitant to seek conventional support. By reducing tobacco smoking- or vaping-related harm and facilitating early behavioural change, TUBSIS 2.0 has the potential to decrease long-term healthcare costs while expanding access to evidence-based digital prevention tools.",[144,28,30,145],"Tobacco Use Disorder","Smoking Tobacco",[147,97,148,149,150],"smoking tobacco","web-based intervention","mindfulness","Health Action Process Approach","2026-04-30",{"date":153,"type":45},"2026-05-05",{"date":155,"type":45},"2025-11-15",{"date":157,"type":22},"2026-08-31",{"name":159,"class":52},"University of Zurich",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":86,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":53},"100619715","pharmacokinetics-and-pharmacodynamics-of-synthetic-nicotine-and-nicotine-analogues-100619715","NCT07348224","Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine and Nicotine Analogues","Inclusion Criteria:\n\n* Men or women, age 18 or older at screening who have used EC with nicotine during at least 10 of the past 30 days\n* Saliva cotinine concentration of \\> 30 ng\u002FmL at screening\n* Ability to communicate well with the investigator and to understand and comply with the requirements of the study\n* Women of child-bearing age engaging in sexual activities which can lead to pregnancy: willingness of using a reliable\u002Fhormonal contraception method during the study (hormonal, e.g. pill, intrauterine devices, or mechanical method, e.g. condom, diaphragm)\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Known hypersensitivity\u002Fallergy to a content of the e-liquids\n* Smoking of more than 5 cigarettes per day in the past 30 days\n* Pregnant or lactating women\n* Intention to become pregnant during the course of the study\n* BMI \\\u003C 18 or \\> 30 kg\u002Fm2 at screening\n* History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening\n* Loss of ≥ 250 mL of blood within 3 months prior to screening, including blood donation\n* Treatment with an investigational drug within 30 days prior to screening\n* Treatment with prescribed or over-the-counter medications with known influence on CYP2A6 function within 1 week prior to screening (with the exception of contraception)\n* History or clinical evidence of any disease (e.g. gastrointestinal tract-disease) and\u002For existence of any surgical or medical condition, which in the opinion of the investigator might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk of toxicity.\n* Legal incapacity or limited legal capacity at screening\n* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol",{"count":167,"type":22},24,[65],"Electronic cigarettes are battery-operated devices that can produce an aerosol by heating a liquid which commonly contains nicotine. In recent years, products containing synthetically produced nicotine and nicotine analogues have entered the market. However, it remains unclear whether these types of nicotine have the same effects as conventional nicotine derived from the tobacco plant. The aim of this study is to investigate the effects of these nicotine types and to gain a better understanding of their respective mechanisms of action.",[35,30,171,172],"Synthetic Nicotine","Nicotine Analogues",[174,175,97],"synthetic nicotine","nicotine analogues","NOT_YET_RECRUITING","2026-04-28",{"date":179,"type":45},"2026-04-29",{"date":181,"type":22},"2026-06-01",{"date":183,"type":22},"2026-12-31",{"name":185,"class":52},"Insel Gruppe AG, University Hospital Bern",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":86,"sex":17,"minAge":194,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":197,"conditions":198,"keywords":202,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100579105","the-canadian-lung-outcomes-in-users-of-vaping-devices-study-100579105","NCT06819969","The Canadian Lung Outcomes in Users of Vaping Devices Study","The Canadian Lung Outcomes in Users of Vaping Devices (CLOUD) Study","CLOUD","Inclusion Criteria:\n\nAdolescent arm:\n\n* Aged ≥12 and \\\u003C19 years old\n* Either 1) use neither combustible cigarettes nor e-cigarettes or 2) use e-cigarettes exclusively\n\nAdult arm:\n\n* Aged ≥19 years old\n* Fall into one of the following categories: 1) use neither combustible cigarettes nor e-cigarettes; 2) use combustible cigarettes exclusively, never using e-cigarettes; 3) use e-cigarettes exclusively, never using combustible cigarettes; or 4) use both combustible cigarettes and e-cigarettes currently\n\nExclusion Criteria:\n\nAdolescent arm:\n\n* Contraindication to pulmonary function testing and cardiopulmonary exercise testing\n* Have smoked combustible cannabis within the last month and\u002For have a combustible cannabis smoking history of \\>1 joint-year\n* Have smoked combustible cigarettes within the last 6 months\n* Have a physician-diagnosed chronic lung disease (such as asthma, cystic fibrosis, or bronchopulmonary dysplasia)\n* Inability to provide written informed consent\n\nAdult arm:\n\n* Contraindication to pulmonary function testing and cardiopulmonary exercise testing\n* Have smoked combustible cannabis within the last month and\u002For have a combustible cannabis smoking history of \\>1 joint-year\n* Currently undergoing treatment for lung cancer\n* Inability to provide written informed consent\n\nNo limitations will be placed on the type of e-liquids used by participants; e.g., e-cigarette users of nicotine, tetrahydrocannabinol, and cannabidiol will be all enrolled.","12 Years",{"count":196,"type":22},500,"Vaping is increasingly popular with both adolescent and adult Canadians, but the long-term health impacts remain unknown. We believe that the tools we currently have to detect lung disease in people who vape may be insufficient and propose new ways to find lung injuries that may impact them over the course of their lives. These include exercise testing, new imaging techniques, and new breathing tests that will demonstrate how vaping may harm their lungs. We will use these tools in both adolescent and adult Canadians to give Canadians who vape important information on the consequences of vaping.",[199,30,200,68,201],"Small Airways Diseases","Vaping Related Disorder","Vaping Behavior",[192,203,97,204,205,206,207,208,209,210,211,212,213,214,215],"small airway injury","vape","e-cigarette","oscillometry","multiple breath washout","chest computed tomography","chest CT","hyperpolarized 129-xenon","MRI","CPET","bronchoscopy","transcriptomics","epigenetics","2026-03-24",{"date":218,"type":45},"2026-03-30",{"date":220,"type":45},"2025-07-25",{"date":222,"type":22},"2029-12-31",{"name":224,"class":52},"University of British Columbia",8,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":240,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":53},"100584151","the-use-of-tdcs-for-vaping-reduction-100584151","NCT06885606","The Use of tDCS for Vaping Reduction","Using Transcranial Direct Current Stimulation (tDCS) for Vaping Reduction in Daily E-cigarette Users: a Pilot Study","Inclusion Criteria:\n\n* The participant must meet all of the inclusion criteria to be eligible for this research study:\n\n  1. Be able to provide informed written consent\n  2. Stated willingness to comply with all study procedures\n  3. Age 18 - 65 years\n  4. Is a daily regular use of nicotine-containing e-cigarette for at least the past 6 months\n  5. Is willing to attend daily appointments for tDCS for two consecutive weeks (Monday through Friday)\n  6. Is not interested in or planning to quit vaping in the next 30 days.\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this research study:\n\n  1. Substance use disorder (other than nicotine dependence) (M.I.N.I. SCID) (confirmed with urine drug screen)\n  2. Current regular use of tobacco cigarettes, nicotine replacement therapy or other medications for smoking cessation\n  3. Unstable psychiatric condition\n  4. Recent clinically significant head trauma\\*\n  5. History of seizures and\u002For epilepsy\\*\n  6. Pacemakers or implanted electrical devices such as cochlear implants\\*\n  7. Metal embedded in the skull\\*\n  8. Skin lesions, open wounds, bruising, or similar injuries on the scalp\\*",{"count":234,"type":22},40,[65],"Project Summary - tDCS for Vaping Reduction\n\nBackground: While the prevalence of tobacco smoking has plateaued over the last several years, the prevalence of nicotine vaping (e-cigarettes) continues to increase exponentially in Canada. Originally touted as a safe alternative to smoking, e-cigarette use or vaping is now most popular among youth and young adults. The high prevalence of e-cigarette use, coupled with growing evidence of associated harms and reports of addiction and difficulties in quitting reinforces the urgent need to develop and test methods to attenuate e-cigarette craving as a step towards developing approaches to vaping cessation that are brief, inexpensive and effective. Non-invasive brain stimulation techniques have become a popular area of research as a treatment option for substance use disorders with growing evidence of their effectiveness for a variety of addictions. One of these techniques, transcranial direct current stimulation (tDCS), has been shown to decrease cigarette craving and consumption. Thus, the purpose of this pilot study is to evaluate the effectiveness of using tDCS for vaping reduction in e-cigarette users.\n\nMethods: This will be a double-blind sham-controlled randomized trial whereby 40 daily nicotine-containing e-cigarette users will be recruited to undergo 10 consecutive daily sessions of tDCS (Monday to Friday for 2 weeks). Participants will be randomized (1:1) to either sham (0mA) or active tDCS (2mA), with the anode at the left dorsolateral prefrontal cortex (DLPFC) and cathode at the right DLPFC. The primary outcome is vaping frequency (puffs\u002Fday and nicotine pods\u002Fweek) at end of treatment (2 weeks). The secondary outcome will be e-cigarette craving. Participants will be followed-up via the phone at 1 month and 3 months post randomization respectively.\n\nImplication: This will be the first treatment study to target vaping reduction. There are currently no established treatment options for e-cigarette addiction and medications traditionally used for smoking cessation only address withdrawal symptoms and not addiction pathology. Thus, findings from this study may be used to inform future designs of vaping reduction strategies or vaping cessation.",[30,238,239],"Addiction","Transcranial Direct Current Stimulation(tDCS)",[241,30,242,243,35],"E-cigarettes","Brain stimulation","tDCS","2026-03-17",{"date":246,"type":45},"2026-03-19",{"date":248,"type":45},"2026-01-01",{"date":250,"type":22},"2026-05",{"name":252,"class":52},"Centre for Addiction and Mental Health",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":86,"sex":17,"minAge":18,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":264,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":53},"100577885","non-invasive-vagus-nerve-stimulation-nvns-and-cognition-in-young-adult-vapers---a-pilot-study-100577885","NCT06804109","Non-invasive Vagus Nerve Stimulation (nVNS) and Cognition in Young Adult Vapers - A Pilot Study","Vaping and Vagal Neuromodulation of Cognition","nVNS","Inclusion Criteria:\n\n* Healthy young adults\n* Age range 18-25 years\n* Current or prior users of e-cigarettes\n\nExclusion Criteria:\n\nParticipants will be excluded from the study if they:\n\n* Have any rash, infection, swelling, cut, soreness, drug patch, surgical scar on the neck area\n* Have any implantable medical device in their body such as a pacemaker, hearing aid implant, or any other metallic\u002Felectronic device\n* Have any hearing or vision problems that are not corrected\n* Are pregnant or breastfeeding\n* Have any learning disabilities\n* Have a medical history of any of the following condition\n* Meningitis\n* Traumatic brain injury\n* Seizure\n* Syncope\n* Schizophrenia\n* Schizoaffective disorder\n* Bulimia (eating disorder)\n* Other serious neurological illness\n* Have a medical history of any of the following cardiac disorder\n\n  * Carotid atherosclerosis or carotid artery disease\n  * Cervical vagotomy\n  * First degree atrioventricular block or prolonged QT interval\n* Are taking any medications for to treat hypertension, arrhythmias, or are on calcium channel blockers","25 Years",{"count":263,"type":22},100,[65],"The purpose of this study is to assess the effects of non-invasive vagus nerve stimulation (nNVS) on cognitive functioning in the users of e-cigarettes or vaping products. The investigators will use a digital wellness companion product (TRUVAGA™ device) that provides mild transcutaneous nVNS. The participants will be randomized to receive either a 2-min nNVS stimulation or control stimulation in the neck region followed by completion of three cognitive tests of attention and executive function.",[30],[97,268,269],"attention","non-invasive vagus nerve stimulation","2026-03-05",{"date":272,"type":45},"2026-03-06",{"date":274,"type":45},"2025-03-18",{"date":276,"type":22},"2028-02-09",{"name":278,"class":52},"Temple University",{"id":280,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":53},"100604157","Inclusion Criteria:\n\n* Age ≥ 18 and ≤65;\n* The ability to give written, informed consent;\n* Fluency in English;\n* Reported interest in quitting nicotine vaping or smoking within the next month;\n* Nicotine dependence, as defined by a score of ≥4 on the 10-question E-cigarette Dependence Inventory (ECDI) or Fagerström Test for Nicotine Dependence (FTND);\n* Smoke or vape nicotine daily for at least the past 90 days, as confirmed by self-report and timeline follow-back methods;\n* Saliva cotinine \\>30ng\u002FmL;\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Use of smoking cessation pharmacotherapy in the past month;\n* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study;\n* Prior adverse drug reaction to varenicline;\n* Receiving or planning to receive other TMS treatments or investigational drugs during course of participation\n* Contraindications to TMS (including seizures, metallic implants, severe existing tinnitus, etc.);\n* Contraindications to MRI (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia);\n* Inpatient psychiatric hospitalization or suicide attempts in the past six months, or recent active suicidal ideation or suicidal behavior identified at enrollment or baseline visits;\n* History of seizures and\u002For history of TBI subtypes associated with elevated seizure risk (e.g. penetrating injury and intraparenchymal hemorrhage)\n* History of unstable neurological illness or major medical illness, such as epilepsy or renal impairment, in the past six months, unless clearly resolved;\n* In the opinion of the investigators, evidence of active problem substance use severe enough to compromise ability to safely participate;\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., claustrophobia, unable to tolerate TMS or MRI procedures, etc.).",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn if a combination of varenicline and accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS to varenicline + sham (inactive) aTMS to see the effect of aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active aTMS + varenicline lead to higher abstinence rates and lower nicotine craving?\n\nParticipants will be asked to:\n\n* Complete 2 brain MRI scans\n* Take varenicline every day for 12 weeks\n* Quit using nicotine products at the end of the second week of varenicline\n* Complete 5 consecutive days (Monday-Friday, uninterrupted) of TMS treatments\n* Complete 12 brief, weekly follow-up visits\n* Complete a brief daily survey each day that they take the study drug",[28,29,30,31,32],[30,34,35,36,37,38,29,39],"2026-01-14",{"date":289,"type":45},"2026-01-16",{"date":291,"type":22},"2026-03-15",{"date":293,"type":22},"2027-12-01",{"name":51,"class":52},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":86,"sex":17,"minAge":302,"maxAge":19,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":307,"conditions":308,"keywords":314,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":53},"100516043","phase-2-understanding-the-clinical-pharmacology-of-marijuana-tobacco-co-administration-100516043","NCT05999383","Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration","CANNIC","Inclusion Criteria:\n\n* Heart rate \\\u003C 105 beats per minute (BPM)\\*\n* Systolic Blood Pressure \\\u003C 160 and \\> 90\\*\n* Diastolic Blood Pressure \\\u003C 100 and \\> 50\\*\n\n  \\*Considered out of range if both machine and manual readings are above\u002Fbelow these thresholds.\n* Body Mass Index (BMI) ≤ 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues)\n* Current regular user of cannabis who smokes or vapes cannabis or THC extracts at least three days a week for the past 3 months or more\n* Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use\n* Current user of inhaled forms of tobacco\u002Fnicotine (cigarette, cigars, e-cigarettes) who use the product daily for the past 3 months or more\n* Saliva cotinine ≥ 30 ng\u002FmL\n\nExclusion Criteria:\n\n* Unstable medical conditions:\n\n  * Heart disease\n  * Seizures\n  * Cancer\n  * Thyroid disease (okay if controlled with medication)\n  * Diabetes\n  * Hepatitis B or C or Liver disease\n  * Glaucoma\n  * Kidney disease or urinary retention\n  * An ulcer in the past year\n  * Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)\n* Hypertension if uncontrolled (meaning participant has a diagnosis, but they are not taking medication\u002Funder treatment (e.g., diet or exercise plan)\n* Drug\u002FAlcohol Dependence\n\n  * Alcohol or illicit drug dependence within the past 12 months (currently in treatment) with the exception of those who recently completed an alcohol\u002Fdrug treatment program\n  * Positive toxicology test at the screening visit (THC \\& prescribed medications okay)\n  * Opioid replacement therapy (including methadone, buprenorphine, or other)\n* Psychiatric conditions\n\n  * Current or past schizophrenia, and\u002For current or past bipolar disorder\n  * Major depression, current or within the past year\n  * Major personality disorder\n  * Participants with current or past minor or moderate depression and\u002For anxiety disorders will be reviewed by the PI \\[study physician\\] and considered for inclusion\n  * History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per PI's \\[study physician's\\] approval\n* Current regular use of any psychiatric medications with the exception of Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate\n* Congenital or acquired immunodeficiency disorders (i.e. HIV, congenital immune deficiency syndrome, chronic diseases)\n* Other disorders (i.e. ICU, malnutrition, immunosuppressive therapy)\n* Traumatic brain injury\n* Recent onset or change (worsening) in cough, fever and\u002For abdominal symptoms (vomiting or pain) in the past two weeks\n* Medications\n\n  * Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs)\n  * Concurrent use of nicotine-containing medications\n  * Any stimulant medications (ex. Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment\n* Other\u002FMisc. Chronic Health Problems\n\n  * Oral thrush\n  * Fainting\n  * Other \"life threatening illnesses\" as per study physician's discretion\n* Pregnancy\n\n  * Pregnancy (self-reported and urine pregnancy test)\n  * Breastfeeding (determined by self-report)\n* Concurrent participation in another clinical trial\n* Inability to communicate in English\n* History of marijuana-induced psychosis or paranoia after smoking marijuana\n* Scoring a 7 or higher on the Severity of Dependence Scale (SDS) for cannabis use\n* Planning to quit smoking or vaping within the next 60 days\n* Planning to quit cannabis use within the next 60 days\n* Uncomfortable with getting blood drawn\n* Willingness to abstain from tobacco smoking and all combustible products for 13 hours before admission\n* Willingness to abstain from smoking\u002Fingestion of cannabis 13 hours before\n* Willingness to abstain from nicotine products 13 hours before each admission","21 Years",{"count":304,"type":22},48,[306],"PHASE2","This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.",[309,310,311,312,313,30],"THC","Cannabis","Cannabis Use","Cannabis Smoking","Tobacco Use",[309,310,315,35,316],"Marijuana","Vape","2026-01-05",{"date":319,"type":45},"2026-01-07",{"date":321,"type":45},"2025-07-01",{"date":323,"type":22},"2028-02-01",{"name":107,"class":52},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":347},"100596062","phase-2-a-trial-of-varenicline-for-e-cigarette-cessation-100596062","NCT07040566","A Trial of Varenicline for E-cigarette Cessation","Investigating Efficacious E-Cigarette Interventions and Cessation Effects on Cancer-Related Biomarkers: A Randomized Trial of Varenicline in Adults","Inclusion Criteria:\n\n* report daily use of an e-cigarette containing nicotine\n* live in Connecticut or South Carolina\n\nExclusion Criteria:\n\n* regular use of other tobacco products besides e-cigarettes\n* medical contraindications for varenicline use\n* current treatment for tobacco cessation\n* lack proficiency in English",{"count":333,"type":22},326,[306],"This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.",[337,30,28],"E-cigarette Use","2025-12-15",{"date":340,"type":45},"2025-12-17",{"date":342,"type":45},"2025-10-14",{"date":344,"type":22},"2030-10-30",{"name":346,"class":52},"Yale University",2,{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":86,"sex":17,"minAge":354,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":359,"conditions":360,"keywords":363,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":53},"100605410","a-hybrid-program-to-prevent-substance-use-risk-among-upper-elementary-school-students-using-a-positive-youth-development-approach-100605410","NCT07162155","A Hybrid Program to Prevent Substance Use Risk Among Upper Elementary School Students Using a Positive Youth Development Approach","Inclusion Criteria: Students will be eligible for participation if they attend a school enrolled in the trial and they are between ages 7-11.\n\nExclusion Criteria: All students will be eligible to participate in intervention implmentation, but survey responses will be excluded from the formal analysis with documentation of significant cognitive impairment as determined by school officials.","7 Years","11 Years",{"count":357,"type":22},3000,[65],"The goal of this randomized controlled trial is to evaluate a psychosocial school-based hybrid intervention which includes traditional classroom sessions and online e-learning modules to reduce risk of vaping and prescription drug misuse as part of a broader positive youth development substance use prevention model. Upper elementary schools (N=30) will be randomized to either an intervention group that will receive a hybrid intervention or a treatment-as-usual control group that will receive existing health education programming. At the end of the intervention period, and at 6- and 12-month follow-up assessments, both groups will be compared on changes in behaviors, norms, attitudes, and knowledge regarding vaping and prescription medication use.\n\nThe main questions the trial aims to answer are:\n\n* Does the intervention lower risk of vaping and prescription drug misuse?\n* Does the intervention increase pro-health norms, attitudes, and knowledge regarding vaping and prescription drug misuse?\n\nParticipants will:\n\n* Attend 1 classroom session per week for 6 weeks (lecture, discussion, small group activities, skills practice).\n* Complete 1 e-learning module per week for 6 weeks (animated didactic content).\n* Students attending schools randomized to the control group will attend existing health education programming.",[30,361,362],"E Cig Use","Prescription Drug Misuse",[364,365,366],"prevention","school-based","positive youth development","2025-08-29",{"date":369,"type":45},"2025-09-09",{"date":371,"type":22},"2026-01",{"date":373,"type":22},"2028-08",{"name":375,"class":376},"Christopher Williams","INDUSTRY",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":86,"sex":385,"minAge":18,"maxAge":386,"enrollmentInfo":387,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":389,"conditions":390,"keywords":393,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":405},"100538912","the-impact-of-e-cigarettes-during-pregnancy-on-childhood-health-outcomes-study-100538912","NCT06297005","The Impact of E-cigarettes During Pregnancy on Childhood Health Outcomes Study","The Impact of E-cigarettes During Pregnancy on Childhood Health Outcomes (ECHO) Study.","ECHO","Inclusion Criteria:\n\n* Women aged 18 or greater and less than 46 years of age at booking\n* Pregnant with a singleton fetus\n* Smokers (exhaled CO reading of greater than or equal to 4) or\n* Self-reported vaper or\n* Dual user (smoker\u002Fvaper)\n* Non-smokers\n* Able to understand and read English.\n* Willing to agree to follow-up for the two-year duration of the study in the postnatal period (ie. unlikely to move out of the catchment area).\n\nExclusion Criteria:\n\n* Women pregnant with twins or higher order multiples\n* Late bookers - defined as booking after 24+0 weeks' gestational age\n* Fetus or infant diagnosed with a major congenital abnormality (major structural abnormality, ie congenital diaphragmatic hernia (CDH), omphalocele, major cardiac defects ie. which require immediate admission to NICU +\u002F- transfer to cardiology for surgery, chromosomal abnormalities, syndromes - Turner's\u002FNoonan's) or a lethal fetal anomaly\n* Any inherited disorder of metabolism or Cystic Fibrosis on Guthrie Card\u002F neonatal blood spot screening\n* History of significant medical disorder in pregnancy e.g. cardiac, haematological, or endocrine disease (including gestational diabetes requiring insulin)\n* Significant maternal psychiatric disorder, e.g. delusional or psychotic disorders, severe depression requiring hospitalisation, use of \\>1 psychotropic drugs for treatment\n* Serious co-morbid addiction issues e.g. opiate abuse, methadone maintenance program\n* Severe intellectual disability or lack of capacity","FEMALE","46 Years",{"count":388,"type":22},1200,"Tobacco smoking in pregnancy is now widely accepted as having adverse health outcomes for both the mother and fetus. Tobacco smoking in pregnancy is associated with increased incidence of miscarriage, stillbirth and preterm birth as well as low birthweight, respiratory infections, wheeze and asthma in childhood. E-cigarettes are a popular method for trying to quit smoking in Ireland and there has been an explosion in the use of e-cigarettes over the past ten years. However, there is currently insufficient evidence on their long-term safety and effectiveness as a smoking cessation tool. E-cigarettes contain varying combinations of compounds and flavours which are used differently in different e-cigarette types, with unknown long-term effects. Research has shown that pregnant women perceive e-cigarettes to be a healthier option when compared with tobacco smoking. But, there is very little known about the long-term health impact of exposure of unborn babies to e-cigarettes during pregnancy.\n\nThe ECHO study will determine what the long-term health outcomes are in children born to mothers who use e-cigarettes during pregnancy. Specifically, we will focus on birth, nutritional, brain development and respiratory outcomes in children. To answer this research question, the ECHO study will recruit infants born to women who use e-cigarettes during pregnancy across three maternity hospitals and follow them up over 2 years. We will invite women at their booking visit to take part in this research study. We plan to also recruit a similar number of both non-smoking and tobacco smoking pregnant women for comparison. We will record a detailed record of e-cigarette and tobacco use by women during pregnancy as well as checking smoking using special monitoring tools. After the baby is born, we will perform growth measurements, neurocognitive assessments and a respiratory questionnaire at 6 months, one year and two years of age.",[30,391,392],"Pregnancy Related","Pediatric Respiratory Diseases",[30,394,395],"Pregnancy","Paediatric health","2024-04-11",{"date":398,"type":45},"2024-04-12",{"date":400,"type":45},"2023-10-09",{"date":402,"type":22},"2027-08-31",{"name":404,"class":52},"University College Dublin",3,{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":86,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":416,"conditions":417,"keywords":419,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":53},"100538496","vaping-adverse-lung-and-heart-events-cohort-100538496","NCT06291597","Vaping Adverse Lung and Heart Events Cohort","VapALERT: A Prospective, Exploratory and Adaptive Cohort Study to Identify Symptomatic and Asymptomatic Pulmonary and Cardiovascular Effects of Vaping","VapALERT","Inclusion Criteria:\n\n* Age 18 years or older\n* Daily electronic cigarette user\n* No respiratory infection in the 4 weeks before a visit\n\nExclusion Criteria:\n\n* Women who are pregnant or breast-feeding.",{"count":415,"type":22},250,"This prospective study assesses the pulmonary and cardiovascular effets of vaping in adult electronic cigarette users with biannual visits and a 5-year follow-up.",[30,418],"Electronic Cigarette Use",[30,316,420,421,422],"Electronic cigarette","Electronic and vaping acute lung injury","EVALI","2024-02-26",{"date":425,"type":45},"2024-03-04",{"date":427,"type":45},"2021-10-14",{"date":429,"type":22},"2032-06",{"name":431,"class":52},"Laval University"]